Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30533340 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11L3MBTL1TBXAS1MMP8 | |
| SCHEMBL22071031 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11L3MBTL1TBXAS1MMP8 | |
| SCHEMBL17746742 | 0.99 | CYP4F2 (0.50) | CYP4F2CYP4A11L3MBTL1TBXAS1MMP8 | |
| SCHEMBL879888 | 0.90 | MMP8 (0.51) | L3MBTL1MMP8TDP1ALDH1A1RECQL | |
| SCHEMBL850989 | 0.90 | MMP8 (0.51) | L3MBTL1MMP8TDP1ALDH1A1RECQL | |
| SCHEMBL8609385 | 0.88 | L3MBTL1 (0.47) | L3MBTL1MMP8TDP1ALDH1A1RECQL | |
| SCHEMBL14782773 | 0.86 | L3MBTL1 (0.46) | L3MBTL1MMP8TDP1ALDH1A1RECQL | |
| SCHEMBL5301360 | 0.85 | L3MBTL1 (0.44) | L3MBTL1MMP8TDP1ALDH1A1RECQL | |
| SCHEMBL6714511 | 0.85 | ALDH1A1 (0.46) | L3MBTL1TDP1ALDH1A1MBOAT4CYP3A4 | |
| SCHEMBL27090651 | 0.85 | L3MBTL1 (0.49) | L3MBTL1MMP8TDP1EPHX2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662209-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-03-06 | — | — | US | disclosed |
| EP-4463451-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024164915-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2024-08-15 | — | — | WO | disclosed |
| WO-2023134712-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | CYP4F2 1227/4885CYP4A11 418/4885L3MBTL1 4809/4885 |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | GPR119, GPR65, GPR55 | CYP4F2 580/4885CYP4A11 341/4885L3MBTL1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.